Fig. 6
From: Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer
Mutational signatures in human bladder cancer cell lines after exposure to bracken extracts and ptaquiloside. a Signature extraction identified 2 novel single base substitution (SBS) signatures, Signatures BFA-A and BFA-B in KU-19–19 cells exposed to BF whole extract (BFA). b Similar signatures, Signature PT-A and PT-B, were identified in KU-19–19 cells exposed to purified PT. For comparison, bovine Signature BF-A is shown (lower panel). c The SBS mutation spectra after 3 days (upper panel) and 14 days (lower panel) of PT exposure at IC50. d The absolute (upper panel) and relative (lower panel) proportion of mutations attributed to Signatures PT-A and PT-B in KU-19–19 cells exposed to PT. NTC is non-toxic concentration; IC20 and IC50 are 20 and 50% inhibitory concentration (of cell growth), respectively; d3, d7, d10, and d14 are the number of days. e The observed and reconstructed SBS spectra from KU-19–19 cells exposed to PT for 10 days (IC50), showing the activity of each signature for each substitution type. f The indel mutation spectrum observed at day 14 (IC50) in KU-19–19 cells exposed to PT. g The doublet substitution spectrum observed at day 14 (IC50) in KU-19–19 cells exposed to PT